<DOC>
	<DOCNO>NCT02539537</DOCNO>
	<brief_summary>French national multicentric phase III trial evaluate chemotherapy Folfirinox gemcitabine locally advance pancreatic carcinoma</brief_summary>
	<brief_title>A Randomized Phase III Trial Comparing Folfirinox Gemcitabine Locally Advanced Pancreatic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>1 . Histologically cytologically confirm adenocarcinoma pancreas 2 . Proven unresectability multidisciplinary discussion involve radiologist surgeon 3 . Locally advanced ( i.e . : metastasis suspicion metastasis ) unresectable tumor : example mesenteric portal vein involvement , &gt; 180° encasement superior mesenteric artery , celiac abutment ( NCCN 2012 criterion ) 4 . Measurable tumor lesion longest diameter ≥ 20 mm use conventional technique ≥ 10 mm spiral CT scan accord RECIST 1.1 criterion 5. WHO Performance status ( PS ) 01 6 . Age ≥18 year 7 . Patient organ function follow : absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Hemoglobin ≥ 10 g/dL platelet ( PTL ) ≥ 75 x 109/L AST/ALT ≤ 2.5x ULN bilirubin ≤ 1.5 x ULN creatinine ≤ 2 x ULN albumin &gt; 0.75 x LLN urea ≤ 2 x ULN 8 . Adequate vital function 9 . Patient childbearing potential ( female patient : study entry menstrual period negative pregnancy test ) must agree use medically acceptable method contraception study 4 month last intake study treatment woman 6 month men . 10 . Patient information sign informed consent form 11 . Public private health insurance coverage 1 . Patient treat cancer pancreatic cancer within 5 year enrolment , exception basal cell carcinoma situ cervical cancer 2 . Patient metastasis history metastasis 3 . Patient grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e . congestive heart failure , myocardial infarction within 6 month baseline ) 4 . Major comorbidity , active infection ( HIV chronic hepatitis B C ) uncontrolled diabetes may preclude delivery treatment . 5 . Preexisting neuropathy ( Grade ≥ 2 ) , Gilbert 's disease genotype UGT1A1 * 28 / * 28 . 6 . Pregnant woman 7 . Fructose intolerance . 8 . Patients currently treat warfarine 9 . Persons deprive liberty guardianship . 10 . Psychological condition , family , sociological geographical situation potentially hamper compliance study protocol followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>locally advanced pancreatic carcinoma</keyword>
	<keyword>FOLFIRINOX</keyword>
</DOC>